为什么认为非索非那定是一种真正的非镇静抗组胺药,不会渗透大脑:系统综述。

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI:10.1080/03007995.2024.2378172
Ignacio J Ansotegui, Jean Bousquet, Giorgio Walter Canonica, Pascal Demoly, Rene Maximiliano Gómez, Eli O Meltzer, Margarita Murrieta-Aguttes, Robert M Naclerio, Nelson Rosario Filho, Glenis K Scadding
{"title":"为什么认为非索非那定是一种真正的非镇静抗组胺药,不会渗透大脑:系统综述。","authors":"Ignacio J Ansotegui, Jean Bousquet, Giorgio Walter Canonica, Pascal Demoly, Rene Maximiliano Gómez, Eli O Meltzer, Margarita Murrieta-Aguttes, Robert M Naclerio, Nelson Rosario Filho, Glenis K Scadding","doi":"10.1080/03007995.2024.2378172","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Fexofenadine is a second-generation inverse agonist of H<sub>1</sub>-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood-brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria.</p><p><strong>Methods: </strong>We performed an electronic literature search using keywords such as fexofenadine, drowsiness, somnolence, sedation, fatigue, cognitive, impairment, psychomotor, driving performances, sleep, rapid eye movement, alertness, clinical study, <i>in vitro</i> study, <i>in vivo</i> study, and pharmacodynamics in the Embase search engine. The review included randomized controlled trials, review articles, systematic reviews, and meta-analyses, together with post-marketing analysis conducted in healthy subjects and patients with allergy and were focused on comparing the antihistaminic potential or safety of fexofenadine with other antihistamines or placebo.</p><p><strong>Results: </strong>Positron emission tomography (PET) and proportional impairment ratio (PIR) data along with other objective tests from various studies confirmed the non-sedative property of fexofenadine. Results of brain H<sub>1</sub>-receptor occupancy (H<sub>1</sub>RO) obtained from PET showed no H<sub>1</sub>RO by fexofenadine, the receptor which is known to cause sedation of H<sub>1</sub> antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose. Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses.</p><p><strong>Conclusion: </strong>Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.\",\"authors\":\"Ignacio J Ansotegui, Jean Bousquet, Giorgio Walter Canonica, Pascal Demoly, Rene Maximiliano Gómez, Eli O Meltzer, Margarita Murrieta-Aguttes, Robert M Naclerio, Nelson Rosario Filho, Glenis K Scadding\",\"doi\":\"10.1080/03007995.2024.2378172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Fexofenadine is a second-generation inverse agonist of H<sub>1</sub>-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood-brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria.</p><p><strong>Methods: </strong>We performed an electronic literature search using keywords such as fexofenadine, drowsiness, somnolence, sedation, fatigue, cognitive, impairment, psychomotor, driving performances, sleep, rapid eye movement, alertness, clinical study, <i>in vitro</i> study, <i>in vivo</i> study, and pharmacodynamics in the Embase search engine. The review included randomized controlled trials, review articles, systematic reviews, and meta-analyses, together with post-marketing analysis conducted in healthy subjects and patients with allergy and were focused on comparing the antihistaminic potential or safety of fexofenadine with other antihistamines or placebo.</p><p><strong>Results: </strong>Positron emission tomography (PET) and proportional impairment ratio (PIR) data along with other objective tests from various studies confirmed the non-sedative property of fexofenadine. Results of brain H<sub>1</sub>-receptor occupancy (H<sub>1</sub>RO) obtained from PET showed no H<sub>1</sub>RO by fexofenadine, the receptor which is known to cause sedation of H<sub>1</sub> antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose. Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses.</p><p><strong>Conclusion: </strong>Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating.</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/03007995.2024.2378172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2024.2378172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

摘要

目的:非索非那定是组胺 H1 受体的第二代反向激动剂,具有高度选择性,在缓解过敏症状方面疗效确切。它的另一个优点是不会穿透血脑屏障,因此不会引起镇静,也不会损害认知功能/精神运动表现。本综述旨在提供基于现有对照研究的证据,以加强非索非那定治疗过敏性鼻炎和荨麻疹患者的非镇静特性:我们在Embase搜索引擎中使用非索非那定、嗜睡、嗜睡、镇静、疲劳、认知、损伤、精神运动、驾驶表现、睡眠、眼球快速运动、警觉性、临床研究、体外研究、体内研究和药效学等关键词进行了电子文献检索。综述包括随机对照试验、综述文章、系统综述和荟萃分析,以及对健康受试者和过敏患者进行的上市后分析,重点是比较非索非那定与其他抗组胺药或安慰剂的抗组胺潜力或安全性:结果:正电子发射断层扫描(PET)和比例损伤比(PIR)数据以及来自不同研究的其他客观测试证实了非索非那定的非镇静特性。正电子发射计算机断层扫描(PET)获得的大脑 H1 受体占用率(H1RO)结果显示,非索非那定没有 H1RO,而众所周知,H1 受体会导致 H1 抗组胺药物的镇静作用。大多数计算 PIR 值为 0 的研究表明,无论剂量大小,非索非那定都是一种无损害的口服抗组胺药。在成人和儿童中进行的临床试验表明,非索非那定的耐受性良好,即使服用高于推荐剂量的非索非那定,也不会产生镇静作用或损害认知/精神运动功能:根据各种参数和为评估非索非那定对镇静和中枢神经系统的影响而进行的临床试验发表的文献表明,非索非那定在临床上有效且无镇静作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.

Objective: Fexofenadine is a second-generation inverse agonist of H1-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood-brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria.

Methods: We performed an electronic literature search using keywords such as fexofenadine, drowsiness, somnolence, sedation, fatigue, cognitive, impairment, psychomotor, driving performances, sleep, rapid eye movement, alertness, clinical study, in vitro study, in vivo study, and pharmacodynamics in the Embase search engine. The review included randomized controlled trials, review articles, systematic reviews, and meta-analyses, together with post-marketing analysis conducted in healthy subjects and patients with allergy and were focused on comparing the antihistaminic potential or safety of fexofenadine with other antihistamines or placebo.

Results: Positron emission tomography (PET) and proportional impairment ratio (PIR) data along with other objective tests from various studies confirmed the non-sedative property of fexofenadine. Results of brain H1-receptor occupancy (H1RO) obtained from PET showed no H1RO by fexofenadine, the receptor which is known to cause sedation of H1 antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose. Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses.

Conclusion: Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1